The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm.

Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...

Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US MANAMA, Kingdom of Bahrain, Feb ...

Danaher, Recursion Pharmaceuticals, Moderna, Thermo Fisher Scientific, AbbVie, Vertex Pharmaceuticals, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to ...

A Nebraska state trooper was killed in the line of duty Monday while responding to a crash on Interstate 80, authorities said ...

Two new MetroRapid lines in East and Southeast Austin will officially start taking passengers this weekend, says CapMetro.

The two new MetroRapid lines are the 800 Pleasant Valley and 837 Expo Center lines, which focus on expanded transit access ...

For the next few weeks, the planet Mars will form an isosceles triangle with the two bright stars marking the heads of the ...

The reshuffle includes the appointment of new executives as well as the creation of new roles within the firm.

Eli Lilly should easily beat the market again in 2025, as it did in 2024. Summit Therapeutics awaits a potentially huge ...

The Bahrain Oncology Centre (BOC) has made medical history by successfully treating a sickle cell disease (SCD) patient using ...